KR102672632B1 - S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물 - Google Patents

S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물 Download PDF

Info

Publication number
KR102672632B1
KR102672632B1 KR1020207034174A KR20207034174A KR102672632B1 KR 102672632 B1 KR102672632 B1 KR 102672632B1 KR 1020207034174 A KR1020207034174 A KR 1020207034174A KR 20207034174 A KR20207034174 A KR 20207034174A KR 102672632 B1 KR102672632 B1 KR 102672632B1
Authority
KR
South Korea
Prior art keywords
formula
compound represented
salt
delete delete
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034174A
Other languages
English (en)
Korean (ko)
Other versions
KR20210019999A (ko
Inventor
웨이 젱
우빈 판
지아왕 구오
Original Assignee
쑤저우 커넥트 바이오파마슈티컬즈, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쑤저우 커넥트 바이오파마슈티컬즈, 엘티디. filed Critical 쑤저우 커넥트 바이오파마슈티컬즈, 엘티디.
Priority to KR1020247018420A priority Critical patent/KR20240094023A/ko
Publication of KR20210019999A publication Critical patent/KR20210019999A/ko
Application granted granted Critical
Publication of KR102672632B1 publication Critical patent/KR102672632B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207034174A 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물 Active KR102672632B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247018420A KR20240094023A (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018420A Division KR20240094023A (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20210019999A KR20210019999A (ko) 2021-02-23
KR102672632B1 true KR102672632B1 (ko) 2024-06-07

Family

ID=68387039

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207034174A Active KR102672632B1 (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물
KR1020247018420A Pending KR20240094023A (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247018420A Pending KR20240094023A (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물

Country Status (13)

Country Link
US (3) US11512078B2 (https=)
EP (2) EP4353719B1 (https=)
JP (3) JP7275253B2 (https=)
KR (2) KR102672632B1 (https=)
AU (1) AU2018421487B2 (https=)
CA (1) CA3099196A1 (https=)
ES (1) ES2978392T3 (https=)
IL (3) IL278464B2 (https=)
MX (1) MX2020011665A (https=)
NZ (1) NZ770323A (https=)
SG (1) SG11202010969UA (https=)
WO (1) WO2019210511A1 (https=)
ZA (1) ZA202007347B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278464B2 (en) * 2018-05-04 2024-10-01 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CA3201000A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315266A (zh) * 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN112778290B (zh) * 2017-01-11 2022-12-06 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
IL278464B2 (en) * 2018-05-04 2024-10-01 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315266A (zh) * 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型

Also Published As

Publication number Publication date
IL278464B2 (en) 2024-10-01
IL312512B1 (en) 2025-11-01
US12202822B2 (en) 2025-01-21
JP2021532165A (ja) 2021-11-25
KR20240094023A (ko) 2024-06-24
SG11202010969UA (en) 2020-12-30
EP4353719B1 (en) 2025-12-24
EP3792258A1 (en) 2021-03-17
JP7651198B2 (ja) 2025-03-26
EP4353719A1 (en) 2024-04-17
JP2023062091A (ja) 2023-05-02
ZA202007347B (en) 2021-10-27
AU2018421487B2 (en) 2024-09-12
JP2025074350A (ja) 2025-05-13
US20210230152A1 (en) 2021-07-29
IL278464B1 (en) 2024-06-01
ES2978392T3 (es) 2024-09-11
EP3792258B1 (en) 2024-02-07
CA3099196A1 (en) 2019-11-07
US20250320200A1 (en) 2025-10-16
IL323665A (en) 2025-11-01
KR20210019999A (ko) 2021-02-23
IL278464A (https=) 2021-03-01
JP7275253B2 (ja) 2023-05-17
IL312512B2 (en) 2026-03-01
BR112020022429A2 (pt) 2021-02-09
NZ770323A (en) 2025-12-19
IL312512A (en) 2024-07-01
US11512078B2 (en) 2022-11-29
MX2020011665A (es) 2021-01-20
WO2019210511A1 (zh) 2019-11-07
US20230050777A1 (en) 2023-02-16
AU2018421487A1 (en) 2020-12-17
EP3792258A4 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
US20250320200A1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CN116987070B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
KR20110120941A (ko) 결정 다형성 형태 631
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
TWI662031B (zh) １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型
CN105461610B (zh) 一种阿普斯特的晶型及其制备方法、药物组合物和用途
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US10759798B2 (en) ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601